Therapeutic advancements in multiple myeloma

Front Oncol. 2014 Sep 4;4:241. doi: 10.3389/fonc.2014.00241. eCollection 2014.

Abstract

Multiple myeloma survival has significantly improved in the latest years due to a broad spectrum of novel agents available for treatment. The introduction of thalidomide, bortezomib, and lenalidomide together with autologous stem-cell transplantation has considerably increased complete remission rate and progression-free survival resulting ultimately in prolonged survival in myeloma patients. Moreover, novel strategies of treatment such as consolidation and maintenance are being used to further implement responses. Finally, a number of new drugs such as carfilzomib and pomalidomide are already in clinical practice, making the future of myeloma patients brighter.

Keywords: IMID’s; bortezomib; elderly; multiple myeloma; new therapies; young.

Publication types

  • Review